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Atrial ﬁbrillation (AF) is the most common arrhythmia in clinical practise and its prevalence is increasing. Over the last 25 years, ﬂecainide has
been used extensively worldwide, and its capacity to reduce AF symptoms and provide long-term restoration of sinus rhythm (SR) has been
well documented. The increased mortality seen in patients treated with ﬂecainide in the Cardiac Arrhythmia Suppression Trial (CAST) study,
published in 1991, still deters many clinicians from using ﬂecainide, denying many new AF patients a valuable treatment option. There is now
a body of evidence that clearly demonstrates that ﬂecainide has a favourable safety proﬁle in AF patients without signiﬁcant left ventricular
disease or coronary heart disease. As a result of this evidence, ﬂecainide is now recommended as one of the ﬁrst-line treatment options for
restoring and maintaining SR in patients with AF under current treatment guidelines. The objective of this article is to review the literature
pertaining to the pharmacological characteristics, safety and efﬁcacy of ﬂecainide, and to place this drug in the context of current therapeutic
management strategies for AF.
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Introduction
Atrial ﬁbrillation (AF)—a supraventricular tachycardia with rapid
uncoordinated atrial activation and a beat-to-beat irregular, fre-
quently rapid ventricular rate—is on the increase, to an extent
that cannot be fully accounted for by factors such as an ageing
population or an increasing prevalence of cardiovascular disease.
1,2
Current guidelines for the treatment and management of AF
recommend heart rate or rhythm control, plus concomitant antith-
rombotic therapy.
3,4 The decision regarding which strategy to
pursue is dependent on several factors, including the pattern of
presentation and the presence, or lack of, underlying conditions.
The latest algorithms recommend initially controlling the ventricu-
lar rate—based primarily on results of randomized trials that found
no mortality or morbidity advantage of either strategy.
5 The same
guidelines, however, direct that prior to choosing long-term rate
control, the future effects of permanent AF should be considered.
It is important to ensure that a window of opportunity to maintain
sinus rhythm (SR) is not overlooked early in the course of AF man-
agement.
3 In a recent position paper it was proposed that certain
patients with AF, in whom SR maintenance strategy is selected,
may beneﬁt from earlier cardioversion.
6 This was prompted by
the growing recognition of the importance of structural changes
that precede the ﬁrst-documented AF episode. Only further
studies will provide the solid data needed to test this hypothesis.
The burden of atrial ﬁbrillation
The prevalence of AF increases with age; it is estimated that 70% of
AF patients are between 65 and 85 years old (median: 75 years).
3
The impact of AF on morbidity and mortality has been thoroughly
documented. The Euro Heart Survey 1 year follow-up data for 80%
of the 5333 participants found that, in patients with permanent AF,
the mortality rate was 8.2%. Furthermore, the mortality rate in
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7 A strong association
(P , 0.0001) between the maintenance of SR and overall survival
was shown in a sub-analysis of the AFFIRM study.
8 The burden
of AF also negatively impacts patients’ quality of life (QOL); for
example, patients can experience palpitations both during exercise
and at rest, and have reduced physical ability,
9 forcing them to
restrict their lifestyles.
Untreated and/or previously undetected episodes of AF induce
electrophysiological and structural changes to the cardiac muscle,
making SR restoration increasingly difﬁcult. This vicious cycle that
contributes to the AF continuum is now described as ‘AF begets
AF’.
10–14 In long-term follow-up studies signiﬁcant proportions
of patients with paroxysmal (intermittent) AF progressed to per-
sistent (chronic) AF.
15,16 Hobbs et al.
17 showed that electrical
remodelling in AF can be reversed in some patients if SR is main-
tained from an early stage, suggesting that prompt recognition and
management of AF is critical.
6
Objectives of this review
Flecainide has been available in Europe since 1982. The Cardiac
Arrhythmia Suppression Trial (CAST) results, published in 1991,
showed increased mortality in patients surviving myocardial infarc-
tion (MI),
18 and caused sales of class IC antiarrhythmic drugs
(AADs) to fall dramatically (by 75%) and there has been a con-
siderable decrease since 1995 in the prescribing of class I AADs
in favour of class III AADs.
19,20 However, the use of ﬂecainide is
supported by results from many randomized clinical trials, and
the drug is recommended as a ﬁrst-line treatment option for
pharmacological cardioversion and maintenance of SR in the
American College of Cardiology/American Heart Association/
European Society of Cardiology (ACC/AHA/ESC) 2006 guidelines
as well as in the 2010 update of the ESC’s European guidelines.
3,4
This review aims to examine the 27 years of accumulated data on
ﬂecainide’s safety and efﬁcacy, and place the drug in its therapeutic
context. It also discusses the pharmacological characteristics of ﬂe-
cainide that are thought to prevent long-term structural and elec-
trophysiological remodelling, as well as maintaining SR (Data on
File. 11th Flecainide PSUR: Meda Pharma GmbH & Co KG, 19
August 2008).
Management of atrial ﬁbrillation
Therapeutic options
Rhythm versus rate control
The options of either restoring and maintaining SR, or controlling
the ventricular rate while allowing AF to persist, are not mutually
exclusive.
3 In the AFFIRM study, a rhythm-control strategy did not
show improved survival over a rate-control strategy in patients
with AF,
8,21 although long-term SR control and anticoagulation
therapy were associated with a lower risk of death.
8 Several
studies, including the large, randomized controlled, PIAF, STAF,
RACE, AF-CHF, HOT cafe ´, and AFFIRM trials, have shown that
in elderly patients with minimal symptoms, rhythm control using
AADs is not associated with improved mortality, morbidity, or
QOL scores, compared with rate control.
21–29 Indeed, data
from the AFFIRM study suggest that, in elderly patients with
coexisting heart disease, the adverse effects of AADs may out-
weigh the beneﬁts of SR restoration.
30 A meta-analysis of the
RACE, STAF, PIAF, HOT CAFE ´, and AFFIRM trials conﬁrmed
that in patients with persistent AF or AF that is likely to be recur-
rent, ventricular rate control with anticoagulation therapy was
equivalent to a rhythm-control strategy in preventing clinical
outcomes.
31
Over time, structural and electrophysiological remodelling
induced by AF may lead to heart failure and intractable AF. The
increasing prevalence of AF in an ageing population, in conjunction
with slowly progressing conditions such as hypertension, coronary
artery disease (CAD), obesity and heart failure, suggests that AF
itself may be the culmination of a protracted process. From this
perspective, the ﬁrst-detected episode of AF is an important
opportunity to prevent disease progression.
Evidence-based treatment guidelines
The 2006 ACC/AHA/ESC guidelines on AF
3 shown in Figure 1
comprehensively outline treatment consensus, clearly delineating
the appropriate options available for each of the different groups
of AF patients encountered. The availability of new data from
recent clinical trials prompted an update of the ESC European
guidelines
4 to include dronedarone as a recommended ﬁrst-line
treatment option for maintenance of SR in patients with paroxys-
mal and persistent AF, except those patents with congestive heart
failure New York Heart Association (NYHA) class III/IV or
unstable congestive heart failure NYHA class II.
Focus on ﬂecainide
Pharmacology of ﬂecainide
Flecainide has local anaesthetic effects and belongs to the class 1C
AADs that block sodium channels, thereby slowing conduction
through the heart. It selectively increases anterograde and retro-
grade accessory pathway refractoriness. The action of ﬂecainide
in the heart prolongs the PR interval and widens the QRS
complex. The effect on the JT interval is insigniﬁcant as ﬂecainide
does not lengthen ventricular repolarization.
32,33
Pharmacokinetics of ﬂecainide
Oral administration of ﬂecainide results in extensive absorption
(bioavailability: 90–95%). Flecainide does not appear to undergo
signiﬁcant hepatic ﬁrst-pass metabolism; a 200–500 mg daily
dose produced plasma concentrations within the therapeutic
range of 200–1000 mg/L (the maximum daily dose is
300 mg).
32,33 The elimination half-life is 12–27 h.
32 Flecainide
undergoes extensive hepatic biotransformation via cytochrome
P450 CYP2D6; inactive metabolites are excreted mostly (85%) in
urine.
Antiarrhythmic effect
At similar concentrations (half maximal inhibitory concentration
[IC50]: 1–2 mM), ﬂecainide blocks the cardiac fast inward Na
+
current (INa) and the rapid component of the delayed rectiﬁer
K
+ current (IKr).
34–36 At higher concentrations (IC50:1 9mM), ﬂe-
cainide also inhibits the late Na
+ current and other cardiac K
+
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36 Flecainide has a high afﬁnity for the open-state Na
+
channels and markedly slows the recovery time constant of
Na
+ channels during diastole (t . 10 s). It has thus been classiﬁed
as a class 1C AAD.
32,33,35,37–39
Flecainide prolongs the action potential duration (APD) in ven-
tricular and atrial muscle ﬁbres, but shortens the APD in Purkinje
ﬁbres—an effect consistent with Na
+ channel blockade.
32,37 In
human atria, ﬂecainide only increases APD and refractoriness in
Figure 1 Evidence-based treatment guideline recommendations for (A) newly discovered AF and (B) maintenance of sinus rhythm following
cardioversion (adapted from Fuster et al.
3). *, Updated European Society of Cardiology recommendations
4; AF, atrial ﬁbrillation; HF, heart
failure; LVH, left ventricular hypertrophy.
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40 Nevertheless,
because ﬂecainide exhibits very slow unbinding kinetics from the
Na
+ channels during diastole, it prolongs the refractoriness to a
greater extent than the APD (i.e. post-repolarization refractori-
ness), decreases excitability and slows intracardiac conduction,
even at normal heart rates, in all cardiac tissues. Clinically, this
effect seems most important at the atrial level. At the ventricular
level it may cause an increase of the stimulation threshold in
patients with an artiﬁcial pacemaker.
Mechanism of atrial ﬁbrillation conversion
In superfused atrial preparations from multiple species, including
dogs and humans driven at fast rates, ﬂecainide reduces the
shortening of the APD, producing tachycardia-dependent pro-
longation of atrial refractoriness.
41 Flecainide also suppresses
atrial APD accommodation to heart rate changes in anaesthe-
tized dogs, leading to rate-dependent prolongation of atrial
refractoriness, which may be important in suppressing AF.
42 In
an experimental canine models of AF, ﬂecainide terminates AF
by causing a tachycardia-dependent increase in atrial effective
refractory period and wavelength, reducing the number of
re-entrant circuits, so that the arrhythmia can no longer
sustain itself.
43,44 However, in goats instrumented with multiple
atrial electrodes, cardioversion of sustained AF induced by ﬂecai-
nide could not be attributed to a prolongation of atrial wave-
length but to a progressive widening in the temporal excitable
gap during AF.
45
Effects on remodelling
Atrial fibrillation is known to induce signiﬁcant electrophysiological
alterations in atrial myocytes and causes signiﬁcant structural
changes (structural remodelling) in atrial tissue.
11,14,46–49 Several
AF-related molecular alterations at the cellular and subcellular
level are due to the activation of different signal transduction
systems.
50–53 These molecular pathways are involved in the regu-
lation of gene expression, cell proliferation, hypertrophy, ﬁbrosis,
and cell death. Histologically, ﬁbrillating tissue shows signs of hiber-
nating myocardium, with evidence of ischaemic or metabolic injury
of the tissue, for example, disintegration of contractile ﬁlaments
(myolysis), accumulation of glycogen, and mitochondrial swelling.
Studies have clearly demonstrated the importance of oxidative
stress for the occurrence of such changes in AF.
54,55 The increased
frequency of depolarization during an AF episode causes a transi-
ent rise in Na
+ entry into atrial myocytes. Cytosolic Na
+ accumu-
lation is believed to worsen myocardial injury, mainly as a result of
increased Ca
2+ entry through the sarcolemmal Na
+–Ca
2+
exchanger.
56 Interestingly, Iwai et al.
57 reported that cytosolic
Na
+ overload may directly alter mitochondrial function by
depolarizing its inner membrane and reducing the rate of oxidative
phosphorylation. Thus, inhibition of Na
+ channels by ﬂecainide
during rapid atrial activation should attenuate the excess cellular
Ca
2+ accumulation and reduce oxidative stress (Figure 2). Impor-
tantly, Na
+ enters via the fast inward Na
+ current and not the
slowly inactivating component of the Na
+ current, known as the
late INa (INaL), which ﬂows during the plateau of the cardiac
action potential and prolongs the QT interval. INaL is more sensi-
tive to ﬂecainide than INa, such that abnormal Na
+ entry via INaL
can be inhibited at drug concentrations that have almost no
effect on peak INa.
58
Preliminary observations support the beneﬁcial effect of ﬂecai-
nide in ﬁbrillating human atrial tissue.
59 In an organotypic human
atrial tissue model, ﬂecainide attenuated pacing-induced oxidative
stress markers and abolished the expression of hypertrophic
kinases and inﬂammatory adhesion molecules. Thus, ﬂecainide
appears to be beneﬁcial for ameliorating AF-induced myocardial
injury and atrial dysfunction.
Figure 2 Inhibition of Na
+ channels by ﬂecainide during rapid atrial activation attenuates excess cellular Ca
2+ accumulation and reduces
oxidative stress. ICa,L, L-type calcium current; ROS, reactive oxygen species; NFkB, nuclear factor-kB.
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Electrophysiological studies in patients with cardiac arrhythmias
demonstrate that ﬂecainide prolongs right atrial (PA interval),
atrioventricular (AV) nodal (AH interval), and His–Purkinje (HV
interval) conduction times.
32,33 In patients with dual AV nodal
pathways, ﬂecainide selectively prolongs retrograde refractoriness
of the fast pathway.
60,61 In patients with accessory AV pathways,
ﬂecainide slows conduction and increases anterograde and retro-
grade pathway refractoriness, but its effects are more pronounced
on the retrograde pathway, often causing complete retrograde
pathway block in patients with basal refractoriness greater than
270 ms.
60–63
Flecainide produces a dose-dependent decrease in intracardiac
conduction, but its effects on intra-atrial and AV nodal conduction
arelesspronouncedthanthoseonHis–Purkinjeconductionandven-
tricular activation.
32,33,60,61,64–67 It prolongs the PR (17–29%) and
QT (4–11%) intervals and the QRS complex (11–27%). Most of
the QT prolongation is due to a widening of the QRS complex,
32,65
so that the JT interval and the rate-corrected QT interval (QTc)
remain unchanged orslightlyincrease(3–8%).
32,33,60,64–70 Flecainide
also prolongs atrial, AV nodal and ventricular refractoriness, but its
effectsonrefractorinessarelesspronouncedthanitseffectsonintra-
cardiacconduction.
32,60,61,64–68,70Flecainidealsoincreasestheendo-
cardial pacing threshold;
61 it may therefore be necessary for
pacemaker-dependent patients to reprogramme their pacemaker.
Flecainide does not affect sinus rate, although bradycardia and
tachycardia have been occasionally reported.
32,33 Flecainide
increases the corrected sinus node recovery time and the sinoatrial
(SA) conduction time in patients with sinus node dysfunction.
61,67
Potential for proarrhythmic effects
Class 1C AADs, including ﬂecainide, may cause supraventricular
proarrhythmia during AF through a regulatory effect on atrial ﬁbril-
latory activity, leading to slow atrial ﬂutter typically at a rate of
200 bpm (1C ﬂutter).
71 Flecainide does not slow AV conduction
and, as a result, a 1:1 ratio of AV conduction to high ventricular
rate may occur. This is associated with aberrant conduction and
a bizarre QRS morphology caused by exaggerated intraventricular
conduction delays.
72 Atrioventricular nodal blocking drugs could
be used to prevent 1:1 conduction and patients should be
instructed to halt exercise when AF recurs.
3,4 Atrial ﬁbrillation
conversion to ﬂutter is considered proarrhythmia. This effect can
be useful since ablation of 1C ﬂutter while continuing ﬂecainide
invariably leads to control of AF symptoms.
73 In addition, the
danger of this type of proarrhythmia is abolished after effective
right atrial isthmus ablation.
Class 1C ventricular proarrhythmia manifests as monomorphic
sinusoidal wide QRS tachycardia or as polymorphic ventricular
tachycardia or ﬁbrillation. Factors associated with ventricular
proarrhythmia risk include decreased left ventricular (LV) function,
ventricular scar tissue, too high a dose and/or rapid dose increases.
Premonitory signs on the surface electrocardiogram (ECG) include
excessive increases in QRS duration.
74–76
Late proarrhythmia is the most important threat to patients
treated with AADs, especially those with supervening ischaemia
or electrolyte disturbances. For class 1C drugs, CAST
77 has
shown that proarrhythmia does not exclusively occur early after
initiation of therapy, but may be ongoing throughout follow-up.
Which factors are involved in late, out-of-hospital proarrhythmia
or sudden death during 1C drug therapy is not clear. Several
factors were implicated in CAST: late development of ischaemia,
congestive heart failure and accumulation of the drug to toxic
levels.
78 All these conditions dynamically promote Na
+ channel
blockade by class I drugs. Increases in the heart rate, occurring
during daily life, may set the stage for late proarrhythmia. For
example, in patients with diminished LV function, during exercise
there may be (sub)acute worsening of congestive heart failure,
possibly due to use dependence of class I drugs.
CAST
18,77,79 results have associated ﬂecainide with debilitating
side effects and increased mortality compared with other treat-
ment options. It is highly likely, however, that the increased mor-
tality observed was due to a greater incidence of ventricular
ﬁbrillation in this population (the so-called proarrhythmic
effect).
78 As a result, ﬂecainide is not recommended for use in
patients with CAD and/or depressed ventricular function.
Potential for haemodynamic effects
Flecainide exerts a negative inotropic effect that may relate to
reduced Na
+ entry with subsequent reduced Ca
2+ entry into
the myocardial cells. In addition, it blocks the intracellular inter-
action between Ca
2+ and the ryanodine receptor; new data pre-
sents ﬂecainide as a novel strategy in preventing diastolic Ca
2+
waves that result in triggered arrhythmias.
80 In ventricular myo-
cytes isolated from a catecholaminergic polymorphic ventricular
tachycardia mouse model, ﬂecainide inhibited cardiac ryandodine
receptor channels by open-state blockade, signiﬁcantly reducing
the spark Ca
2+ mass without causing any compensatory increases
in the sarcoplasmic reticulum Ca
2+ content. Intravenous (iv) ﬂecai-
nide transiently reduces cardiac output and stroke volume.
81
During chronic oral therapy, ﬂecainide has minimal effects on
blood pressure,
32,40,64,69,82–84 and the LV ejection fraction
(LVEF) remains unchanged, or slightly decreases, in patients with
normal, or nearly normal, ventricular function.
64,68,69,85,86
However, ﬂecainide signiﬁcantly reduces stroke volume index
and LVEF and increases right atrial and pulmonary capillary
wedge pressures in patients with coronary heart
disease,
64,68,69,84–86 acute MI,
85,87 or LV dysfunction.
84,86,88
Initiating ﬂecainide treatment
According to the present guidelines ﬂecainide is indicated in
patients with normal heart, hypertension, minor heart disease,
and good LV function, this likely applied to some 80% of the
patients with paroxysmal AF (PAF) and some 50% of the patients
with persistent AF.
3,4 Overall, the ‘real-life’ use of ﬂecainide is low:
the Euro Heart Survey on AF indicates that around 17 and 13% of
paroxysmal and persistent AF patients are treated with class IC
agents including ﬂecainide or propafenone, respectively.
89 Prior
to initiating ﬂecainide treatment, patients should be checked for
contraindications including structural heart disease, second- or
third-degree AV block, left bundle branch block, right bundle
branch block (when associated with left hemiblock), asymptomatic
non-sustained ventricular tachycardia, cardiogenic shock, reduced
cardiac output (LVEF , 35%), post-MI, and signiﬁcant renal or
hepatic impairment. Electrocardiogram parameters determined
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In addition, the presence of ischaemia and tolerance to exercise
should be determined. After initiation of ﬂecainide, use-dependent
QRS widening may be assessed during a formal exercise test.
During treatment, the QRS interval should be regularly
monitored.
3
In AF, oral ﬂecainide should be administered in a hospital setting
with rhythm monitoring, starting at 50 mg BID and increased by
50 mg BID every 4 days until efﬁcacy is achieved.
90 After adminis-
tration of ﬂecainide heart rhythm should be monitored for at least
8 h but physicians should check their local guidance for mandatory
hospitalization during titration. The maximum recommended oral
dose is 300 mg/day. For patients who are not able to receive
high doses of standard oral ﬂecainide and those with renal
failure, a sustained-release capsule can be used. To achieve
control of class IC atrial ﬂutter, some physicians routinely use
digoxin or a beta-blocker in addition to ﬂecainide.
91
To achieve a more rapid effect in an emergency, a bolus dose of
ﬂecainide can be administered as a slow injection of 1–2 mg/kg
over 10 min, or in divided doses, up to a maximum of 150 mg,
while monitoring blood pressure. If these are not effective, a con-
tinued infusion of ﬂecainide can be given at 1.2–1.5 mg/kg/h during
the ﬁrst hour and 0.12–0.25 mg/kg/h during subsequent hours for
no longer than 24 h. During the acute phase the QRS is usually
continuously monitored but also measured with a 12-lead ECG
performed at the end of bolus and at 15 min, 30 min, 1, 2, and
3 h intervals. In patients receiving higher doses, ECG and plasma-
level monitoring are strongly recommended. The maximum cumu-
lative dose over the ﬁrst 24 h should not exceed 600 mg. Flecai-
nide can also be used for hospital outpatients and in the elderly,
although plasma clearance is slower than in younger individuals.
Clinical efﬁcacy
Cardioversion
Flecainide is highly effective in the acute setting for cardioversion of
AF. In haemodynamically stable patients with acute-onset AF
(,48 h duration) and preserved LV function, ﬂecainide restores
SR in up to 95% of patients within 1 h from the start of the infu-
sion. A pooled analysis of eight randomized controlled trials by
the US Agency for Healthcare Research and Quality (AHRQ)
showed that acute treatment with ﬂecainide was associated with
conversion rates of between 52 and 95% (Figure 3).
92 A further
single-blind, randomized, comparative study showed that SR was
achieved in 90% of patients treated with ﬂecainide (2 mg/kg
bolus, plus second bolus of 1 mg/kg if the ﬁrst dose did not
convert), compared with 72% of patients treated with propafenone
and 64% of patients treated with amiodarone (P ¼ 0.008).
93
Although patients may also spontaneously convert to SR, this
Figure 3 Proportion of subjects with successful pharmacological conversion (adapted from McNamara et al.
92). *, Control treatment includes
groups receiving placebo, Verapamil, diltiazem, or digoxin; **, Vertical lines represent 95% conﬁdence intervals for the proportion of subjects
with successful pharmacological conversion; +, n equals the number of trials evaluating each comparison.
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nide signiﬁcantly foreshortens conversion to SR. Both iv and oral
ﬂecainide can, therefore, play important roles in shortening the
periods of symptomatic AF, thereby limiting complaints.
94
Flecainide is also a safe and effective agent for termination of AF
in patients with Wolff–Parkinson–White (WPW) syndrome. Clas-
sically, iv procainamide is suggested as the ﬁrst-line drug,
3 but this is
less effective in terminating AF. By reducing the safety of conduc-
tion over the accessory pathway, ﬂecainide blocks conduction and
slows the ventricular rate. Flecainide infusion during AF in WPW
patients is therefore extremely safe. In addition to rate slowing, ﬂe-
cainide eventually converts AF to SR.
95
The efﬁcacy and safety of oral (up to 300 mg in a unique loading
dose) and iv (up to 150 mg in 10 min) regimens of ﬂecainide
acetate have been clearly demonstrated (Table 1). In current guide-
lines, ﬂecainide (oral or iv) has received a class I, level A rating for
cardioversion in AF.
3 Approximately half of the responding patients
convert within 3 h of the oral dose or within 1 h of the initial infu-
sion time.
94,96–98 The single loading oral dose of ﬂecainide has a
conversion rate of 50–60% at 3 h and 75–85% at 6–8 h.
96,97,99
A loading oral dose (600 mg) of propafenone has also been
shown to be effective for cardioversion of AF, with conversion
rates around 72–76% at 6–8 h, although taking longer, especially
in the iv infusion (3–6 h average).
99,100
No serious adverse events were reported with regimens used
when patients were ECG monitored and in a resting condition.
Atrial ﬂutter with 1:1 conduction (producing fast ventricular
rates) can occur immediately before conversion with a rate of
0.2%, particularly during exercise. A long asystolic pause may
also occur at the time of conversion. These constitute the main
reasons for administering the ﬁrst loading oral dose under strict
ECG and clinical control in a hospital setting.
3,29,100
Thereafter, a single bolus dose may be considered in an outpa-
tient setting, after treatment has been considered safe, as a con-
venient method to cardiovert patients at home. This, so-called,
‘pill-in-the-pocket’ approach has become a means of treating
patients with paroxysmal or persistent symptomatic AF with an
average ventricular rate of 70/min or greater.
29 However, this
strategy is only suitable for selected patients; the episode has to
be of recent onset (within 48 h) in a patient with normal QRS dur-
ation and of good LV function, without SA or AV nodal dysfunc-
tion, bundle branch block, structural cardiomyopathy or Brugada
syndrome. The advantage of the pill-in-the-pocket approach,
despite the normally high rate of spontaneous conversion, is
mainly related to the shorter time scale for conversion associated
with ﬂecainide, which may equate to a better QOL although more
evidence is required.
101
Maintenance of sinus rhythm
In PAF, ﬂecainide has been shown to signiﬁcantly reduce the
number of AF recurrences, and lengthen the time between epi-
sodes.
102–107 A meta-analysis of 60 studies with ﬂecainide
showed that 65% of patients were responsive to treatment in
the short-term, and 49% in the long-term, indicating that the clini-
cal beneﬁt of ﬂecainide for maintaining SR is sustained.
105 A litera-
ture analysis suggests that ﬂecainide may be more effective than
several other AADs for maintaining SR following cardioversion
(Table 2), although direct head-to-head comparisons are not avail-
able and these rates, taken with 12-lead ECGs may be higher than
those seen under current monitoring guidelines.
108
Flecainide also reduces the symptoms associated with AF; signiﬁ-
cantly more patients receiving ﬂecainide reported suppression of
palpitations (P , 0.001), tachycardia (P ¼ 0.027), and chest pain
(P ¼ 0.023), compared with those receiving placebo.
102 Moreover,
one out of three patients (31%) in the ﬂecainide group reported
‘complete freedom from symptoms’, compared with only 9% in
the placebo group.
Clinical safety
In general, class 1C AADs are associated with speciﬁc risk factors
for proarrhythmic events (Table 3). The use-dependent electro-
pharmacological effects are enhanced at higher heart rates; there-
fore, the electrophysiological effects are most marked in the atria
during AF because the intrinsic atrial rate is so high. Hence, dele-
terious effects (e.g. ventricular proarrhythmia, negative inotropy,
and AV block) are less of a risk at the doses used to stop AF.
The potential downside of use dependence is that, during SR,
atrial (and ventricular) effects are minor, reducing the preventative
effects. However, class 1C AADs suppress premature beats,
suggesting that other mechanisms, such as suppression of (abnor-
mal) automaticity, may play a role.
32,33
The results of CAST raised important issues regarding the safety
of AADs to suppress arrhythmias or prevent arrhythmia recur-
rences.
18,77,79 The results of CAST deterred physicians from
using ﬂecainide, even in patients without any demonstrable cardio-
vascular disease. One of the most difﬁcult issues is that patients
may develop coronary disease, ischaemia and/or structural heart
disease while receiving chronic ﬂecainide. Patients who are effec-
tively treated but who have, for example, non-signiﬁcant CAD as
detected by CT angiogram, may continue ﬂecainide but should
be instructed about warning symptoms, including unexplained
fatigue, new or increased chest pain, or syncope. Physicians
should perform an exercise test and regular ECGs, and patients
should monitor their symptoms and report any problems.
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Most importantly, background diseases such as hypertension and
coronary disease should be addressed aggressively with preventa-
tive therapy once detected. Patients successfully treated with ﬂe-
cainide but who develop vascular disease may continue ﬂecainide
treatment if these precautions are followed.
When used in appropriately selected patients, ﬂecainide has
shown a good safety proﬁle, as demonstrated by more than 25
years’ of cumulative experience with the drug throughout the
Europe and the USA. A recent systematic review determined the
incidence of ventricular arrhythmias in ﬂecainide-treated patients
to be ,3%.
110 A meta-analysis of 122 ﬂecainide studies included
4811 patients with supraventricular arrhythmias but no signiﬁcant
signs of ventricular damage, with a mean exposure time of
241+224 days. Compared with controls, ﬂecainide was associ-
ated with a lower incidence of proarrhythmic episodes (2.7 vs.
4.8%), angina symptoms (1 vs. 1.3%), hypotension (0.8 vs. 1.3%),
diarrhoea (0.7 vs. 2.8%), headache (2.0 vs. 2.9%), and nausea
(1.6 vs. 1.8%).
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The strengths of this meta-analysis are its comprehensiveness
and that all included studies were prospective; however, the
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Table 1 Prospective trials on oral loading pharmacologic conversion of paroxysmal and persistent atrial ﬁbrillation
Study Patient group Study type (level of
evidence)
Outcomes Key results Study weaknesses
Capucci et al.
97 62 patients with recent onset AF (≤7 days), placebo versus
amiodarone iv bolus followed by infusion or ﬂecainide po
Randomized single
blind trial
Conversion to
SR
As a percentage Small numbers; Placebo group
discontinued monitoring after 8 h
At 3 h Placebo 29, amiodarone 16,
ﬂecainide 68
At 8 h Placebo 48, amiodarone 37,
ﬂecainide 91
At 12 h Amiodarone 47, ﬂecainide 91
At 24 h Amiodarone 89, ﬂecainide 95
Donovan et al.
98 98 patients with acute onset AF (≤72 h), placebo vs. amiodarone
iv or ﬂecainide iv
Randomized
controlled trial
Conversion to
SR
Small numbers; Power not shown
,2 h Placebo 7/32, amiodarone 11/
32, ﬂecainide 20/34
.2 and ,8 h Placebo 18/32, amiodarone 19/
32, ﬂecainide 23/34
Boriani et al.
96 417 patients with recent onset AF (≤7 days), placebo versus
amiodarone iv, ﬂecainide po, propafenone iv or propafenone po
Cohort Conversion to
SR
As a percentage
At 1 h Placebo 9, amiodarone 6,
ﬂecainide 13
At 3 h Placebo 18, amiodarone 25,
ﬂecainide 57
At 8 h Placebo 37, amiodarone 57,
ﬂecainide 75
Martinez-Marcos
et al.
93
150 patients with acute onset AF (≤48 h). Amiodarone iv versus
ﬂecainide iv or propafenone iv
Randomized
single-blind trial
Conversion to
SR
As a percentage
At 1 h Amiodarone 14, ﬂecainide 29
At 8 h Amiodarone 42, ﬂecainide 82
At 12 h Amiodarone 64, ﬂecainide 90
AF, atrial ﬁbrillation; SR, sinus rhythm; iv, intravenous; po, per os.
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8quality of the studies differed markedly, and follow-up was mostly
relatively short. Despite this, the conclusions are still valid; ﬂecai-
nide appears to be safe for patients with supraventricular arrhyth-
mias without detectable heart disease, and it may contribute to
suppression of AF- or SVT-related symptoms. The author con-
cluded that the recommendation to perform intensive diagnostic
tests to exclude associated cardiovascular disease, before initiating
and during ﬂecainide treatment, is valid.
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Mortality attributable to ﬂecainide in the meta-analysis was
lower than expected in the general population (total mortality:
0.166%; mortality rate per 100 patient years: 0.397). Compared
with historical controls, the patient population of an AF study at
Duke University (Durham, NC, USA) was much smaller, although
it contained a signiﬁcant proportion of patients with extensive
underlying heart disease.
112 There was no evidence of increased
or lower proarrhythmia events with ﬂecainide compared with
the compiled control drugs.
Information for ﬁrst-time hospitalizations for AF between 1995
and 2004 was drawn from a nationwide registry in Denmark.
113
Within this unselected cohort (n ¼ 151 500) there was no associ-
ation between antiarrhythmic treatment (ﬂecainide, propafenone,
sotalol, or amiodarone) and any increased risk of death and
demonstrated that appropriate selection of patients for AAD
therapy did not increase mortality as suggested in other trials
such as CAST. Annualized mortality rates (as per year per 100
person-years) were lower with class IC agents (ﬂecainide: 2.54;
propafenone: 4.25; sotalol: 5.29; and amiodarone: 7.42), and few
deaths were observed within 30 days of starting AADs, when
proarrhythmic drug effects are most likely. This study was
limited by its retrospective non-randomized nature, but the
results are nonetheless promising.
In a study evaluating the cardiac safety of 200 mg ﬂecainide
acetate controlled-release formulation for the prevention of PAF,
4 of 227 patients had a maximum QRS value .100 ms under
treatment. Bradycardia (13.2%; n ¼ 17/129) and ventricular extra-
systoles (10.6%; n ¼ 11/104) were the most frequently identiﬁed
proarrhythmic effects. Atrioventricular block (4.0%; n ¼ 9/227),
supraventricular tachycardia (2.2%; n ¼ 5/227), bundle branch
block (1.8%; n ¼ 4/227), and AF (1.3%; n ¼ 3/227) were the
most frequent drug-related cardiac adverse events.
114 In this
study, however, there was no comparison with controls. It was
concluded that the cardiac adverse event rate was ‘consistent
with data from the literature for patients with supraventricular
tachyarrhythmia’. The observation that QRS widening is the main
cause of ﬂecainide-related adverse effects suggests that
controlled-release formulations may be safer than standard
preparations.
The place of ﬂecainide in atrial ﬁbrillation
Flecainide is one of the ﬁrst-line treatment recommendations for
maintaining SR following cardioversion in the current guidelines.
3,4
These guidelines advise that patients with recurrent PAF may
beneﬁt from rhythm control with ﬂecainide, particularly younger
age groups with normal cardiac function. In the acute setting, ﬂe-
cainide is recommended for pharmacological cardioversion of
PAF of no more than 7 days’ duration, and there is also strong evi-
dence supporting the use of ﬂecainide prior to electrical cardiover-
sion. One study found pre-cardioversion ﬂecainide use resulted in
more successful ﬁrst shocks in comparison with placebo (65 vs.
30%, respectively; P ¼ 0.04).
115 Another study concluded that
‘Intravenous ﬂecainide reduces atrial deﬁbrillation threshold in
patients treated with low-energy internal atrial cardioversion
which results in lower shock-induced discomfort. Additionally, ﬂe-
cainide may increase the procedure success rate in patients with
chronic persistent atrial ﬁbrillation’.
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The case for early treatment
It is easy to underestimate the impact of AF. By the time AF is con-
ﬁrmed, remodelling will already be underway; the ﬁrst-
documented episode may be only one of a series of unrecognized
episodes.
10,14,117 If left untreated, the condition will become
chronic through its own self-perpetuating mechanism.
15 Clinicians
who see many AF patients are more aware of the impact of AF on
patients’ wellbeing; frequently AF patients do not fully appreciate
the extent to which their QOL has been diminished until SR has
been restored.
Atrial ﬁbrillation is widely accepted as a condition of the elderly;
however, around half of patients presenting with PAF are ,60
years old. Nevertheless, current treatment guidelines are based on
large randomized controlled clinical trials, such as the AFFIRM,
................................................................................
Table 2 Relapse rates for different antiarrhythmic
drugs reported in the literature
a
Mean relapse rate (range) Studies (n)
No drug 69% (44–85) 10
Quinidine 59% (46–89) 11
Disopyramide 51% (46–56) 3
Propafenone 61% (54–70) 3
Flecainide 38% (19–51) 3
Sotalol 58% (51–63) 3
Amiodarone 47% (17–64) 4
aMinimum 6-months follow-up.
Adapted from Levy et al.
108
................................................................................
Table 3 Ventricular proarrythmia risk factors for class
1C antiarrhythmic drugs
Risk factors
Wide QRS (.120 ms), Brugada ECG sign
Low LVEF, CHF
Structural heart disease, CAD
High rate (use-dependent effect)
High dose
Hypokalaemia
Severe renal failure (creatinine clearance ≤ 35 mL/min/1.73 m
2)
Excessive QRS increase (.150% from baseline)
CAD, coronary artery disease; CHF, chronic heart failure; LVEF, left ventricular
ejection fraction; ECG, electrocardiogram.
25 years—a review of ﬂecainide 169RACE, and STAFstudies, which had meanpatient ages of 70, 68, and
66 years, respectively.
21–23 In these studies, patients also had estab-
lished persistent AF at inclusion and most had other cardiovascular
risk factors, restricting the choice of therapy. There is an increasing
view among clinicians that younger, healthier patients should be
restored to and maintained in SR through aggressive treatment at
the very ﬁrst sign of the illness.
6 In this population, maintaining SR
is vital so as to interrupt the process of atrial remodelling, and to
improve QOL
101,118,119 and long-term survival.
8 A recent position
paper proposed a tightening of the treatment guidelines for newly
discovered AF to recommend early treatment with AAD therapy
to restore the patient to SR.
6
When selecting the appropriate AAD, the treatment should be
tailored to each patient; the often complex presentation of AF
makes this a challenging task. Flecainide has been on the market
for 27 years, and its capacity to reduce AF symptoms and provide
long-term restoration of SR has been well documented.
92,93,102–
108 However, the increased mortality reported in CAST still
deters many clinicians from using a class 1C AAD. This denies
many new AF patients a valuable treatment option. The increased
mortality seen in patients treated with ﬂecainide in CAST is now
viewed as having been caused by proarrhythmic events in elderly
patients with signiﬁcant pre-existing cardiovascular comorbidity.
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Important treatment decisions should not be based on this single
study; there is now a body of evidence supporting the use of ﬂecai-
nide, clearly demonstrating thatin AF patients without signiﬁcant LV
disease or CAD, the drug has a favourable safety proﬁle with a low
incidence of proarrhythmic and other cardiac and non-cardiac
adverse events. As a result of this evidence, ﬂecainide is now rec-
ommended as one of the ﬁrst-line treatment options for restoring
and maintaining SR in patients with AF under the current ACC/
AHA/ESC guidelines and the updated ESC guidelines.
Conclusions
Atrial ﬁbrillation is a ‘ticking bomb’. The increasing prevalence of
AF may result in an epidemic of associated heart disease with a
major impact on patients QOL. Early detection and aggressive
treatment can help break the vicious circle where ‘AF begets AF’.
Over the last 25 years, ﬂecainide has been used extensively
worldwide. The abundance of experience and knowledge gathered
during this period supports ﬂecainide as a safe and effective option
for achieving and maintaining SR in younger patients without
co-existing structural heart disease. Furthermore, our increased
understanding of the pathophysiological mechanisms underlying
AF provides a strong rationale for early treatment with ﬂecainide
to prevent long-term complications.
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